OIG

Amgen pleads guilty, takes CIA in $762 million False Claims Act case

Amgen pleads guilty, takes CIA in $762 million False Claims Act case

By

Amgen "marketed the spread" between the price practices pay for Aranesp and that patients pay as a means of driving sales—to the point of having speakers tell docs that they could make a million more each year by prescribing the Amgen anemia drug over its competitor, Procrit.

GSK in biggest-ever $3b marketing fraud settlement

GSK in biggest-ever $3b marketing fraud settlement

By

GlaxoSmithKline will pay $3 billion to settle state and federal charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug Avandia.

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

By

Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.

Pharmas ask FDA for guidelines on off-label info

By

Seven large pharmas filed a citizen petition with FDA asking for guidance on communication about off-label uses for products.

AstraZeneca settles Seroquel off-label suit for $520m, CIA

AstraZeneca settles Seroquel off-label suit for $520m, CIA

By

AstraZeneca agreed to pay $520 million and enter a five-year Corporate Integrity Agreement to settle a federal case against the company for off-label marketing of Seroquel, the Departments of Justice and Health and Human Services' Healthcare Enforcement Action Team announced.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.